ADC CDMOs — Bioconjugation, HPAPI & GMP Rankings · 2026
61
CDMOs tracked
10
Fully scored
7
With FDA records
31
FDA inspections
94
EMA/MHRA GMP certs
2
Warning letters
Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.
Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 11 NAI (no action), 18 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (24), UNITED KINGDOM (21), Denmark (18), Germany (11), UNITED STATES (8).
Last updated 2026-08-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 2 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 3 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 4 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
83.7 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 5 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.6 | 95.7 | 5 insp · 13 GMP | — | 0 programs |
| 6 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 7 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings; legacy US operations headquartered in Somerset, NJ)
|
76.5 | 79.3 | 12 insp · 35 GMP | — | 0 programs |
| 8 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 9 |
Abzena
San Diego, CA; Bristol, PA; Cambridge, UK
|
64.0 | — | — | Available | 0 programs |
| 10 |
SB
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
|
61.5 | — | — | Available | 0 programs |
| — |
Icosagen
Tartu, Estonia
|
Profiled | — | — | — | 0 programs |
| — |
WuXi XDC
Shanghai, China
|
Profiled | — | — | — | 0 programs |
| — |
Altruist Biologics
Suzhou, China
|
Profiled | — | — | Available | 0 programs |
| — |
Olon Group
Rodano (Milan), Italy
|
Profiled | — | — | — | 0 programs |
| — |
Olon
Rodano (Milan), Italy
|
Profiled | — | — | — | 0 programs |
| — |
Fermion (Orion Group)
Espoo, Finland
|
Profiled | — | — | — | 0 programs |
| — |
Meiji Seika Pharmatech Co., Ltd.
Odawara, Japan
|
Profiled | — | — | — | 0 programs |
| — |
PCI Pharma Services
Philadelphia, PA
|
Profiled | — | — | — | 0 programs |
| — |
Sterling Pharma Solutions
Cramlington, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Veranova
Devens, MA
|
Profiled | — | — | — | 0 programs |
| — |
Mabion S.A.
Konstantynów Łódźki, Poland
|
Profiled | — | — | — | 0 programs |
| — |
EirGenix
Zhubei City, Taiwan
|
Profiled | — | — | — | 0 programs |
| — |
Sai Life Sciences
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Cambrex Corporation
East Rutherford, NJ
|
Profiled | — | — | — | 0 programs |
| — |
BE Biosol (formerly SGI Pharma / Biological E, Samirpet)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Ardena
Ghent, Belgium
|
Profiled | — | — | — | 0 programs |
| — |
EUROAPI
Paris, France
|
Profiled | — | — | — | 0 programs |
| — |
AsymBio
Shanghai, China
|
Profiled | — | — | — | 0 programs |
| — |
Aarti Pharmalabs Limited
Mumbai, India
|
Profiled | — | — | — | 0 programs |
| — |
Novelty Nobility Inc.
Seoul, South Korea
|
Profiled | — | — | — | 0 programs |
| — |
Pierre Fabre CDMO
Toulouse, France
|
Profiled | — | — | — | 0 programs |
| — |
Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)
Hangzhou, China
|
Profiled | — | — | — | 0 programs |
| — |
Curapath
Spain (exact city not disclosed publicly)
|
Profiled | — | — | — | 0 programs |
| — |
Biopharma Group
Swindon, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Chime Biologics
Wuhan, China
|
Profiled | — | — | — | 0 programs |
| — |
SEQENS Pharmaceutical Solutions (broader group)
Écully, France
|
Profiled | — | — | — | 0 programs |
| — |
Asymchem / AsymBio
Tianjin, China (primary manufacturing); Morrisville, NC (US HQ)
|
Profiled | — | — | — | 0 programs |
| — |
Corden Pharma (Colorado site / formerly AmbioPharm combined)
Boulder, CO
|
Profiled | — | — | — | 0 programs |
| — |
Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma)
Lianyungang, China
|
Profiled | — | — | — | 0 programs |
| — |
Fresenius Kabi
Bad Homburg, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Genmab (via ProfoundBio acquisition)
Copenhagen, Denmark
|
Profiled | — | — | — | 0 programs |
| — |
WuXi STA (Shanghai SynTheAll Pharmaceutical Co., Ltd.)
Shanghai, China
|
Profiled | — | — | — | 0 programs |
| — |
Laurus Labs
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Axplora
Raubling, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Novasep
Lyon, France
|
Profiled | — | — | — | 0 programs |
| — |
Cerbios-Pharma
Lugano, Switzerland
|
Profiled | — | — | — | 0 programs |
| — |
Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma)
Tokyo, Japan
|
Profiled | — | — | — | 0 programs |
| — |
ICROM S.r.l.
Concorezzo, Italy
|
Profiled | — | — | — | 0 programs |
| — |
Jetpharma SA
Balerna, Switzerland
|
Profiled | — | — | — | 0 programs |
| — |
Almac Group
Craigavon, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
National Biologics Facility (NBF)
Brisbane, Queensland, Australia
|
Profiled | — | — | — | 0 programs |
| — |
Dr. Reddy's Laboratories
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Zencore Biologics
Shanghai, China (R&D facility: Maryland, USA)
|
Profiled | — | — | — | 0 programs |
| — |
ISPE Good Practice Guide: SMEPAC – Standardized Methodology for Evaluation of Pharmaceutical Airborne Particle Emissions (3rd Edition)
Tampa, FL (ISPE Global HQ)
|
Profiled | — | — | — | 0 programs |
| — |
Anthem Biosciences
Bengaluru, India
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
| — |
Apitoria Pharma Private Limited
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Douglas CDMO
Auckland, New Zealand
|
Profiled | — | — | — | 0 programs |
| — |
VerGo Pharma Research Laboratories Pvt. Ltd.
Verna, Goa, India
|
Profiled | — | — | — | 0 programs |
| — |
CDMO Industry — Market Size & Growth (2026)
Global
|
Profiled | — | — | — | 0 programs |
| — |
Quotient Sciences
Nottingham, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Altasciences
Laval, Canada
|
Profiled | — | — | — | 0 programs |
What to evaluate in a ADC (Antibody-Drug Conjugate) CDMO
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Integrated ADC CDMOs vs multi-site coordination
ADC manufacturing has four distinct steps: monoclonal antibody production, payload synthesis, linker chemistry, and bioconjugation. Full-service ADC CDMOs — a small set including Lonza, WuXi Biologics, and Piramal Pharma Solutions — handle all four in-house. Most CDMOs specialize in one or two steps and coordinate with sponsors for the rest. Fully integrated is faster and simplifies comparability, but often comes with less flexibility on payload chemistry. Sponsors should map which steps each CDMO handles internally vs externally and price the coordination overhead accordingly — a two-CDMO ADC program typically adds 3–6 months of transfer and comparability work.
HPAPI containment for ADC payloads — what to ask
ADC payloads (tubulin inhibitors like MMAE and DM1, topoisomerase inhibitors like Dxd, DNA-damaging agents like PBDs and calicheamicin) are Category 3–5 high-potency compounds requiring specialized containment. CDMOs vary widely on containment maturity: dedicated HPAPI suites, negative-pressure isolators, single-use containment technology, and validated occupational exposure limits (OEL) below 1 µg/m³ (OEB-5). The FDA inspection record shown in the ranked table above reflects containment discipline under regulator scrutiny. Sponsors should also verify the CDMO's HPAPI-specific incident history and whether payload production is co-located with conjugation or shipped between sites.
Conjugation platform — random vs site-specific
Random cysteine or lysine conjugation is the mature ADC platform used by Kadcyla, Adcetris, Enhertu, Trodelvy and other approved ADCs; most CDMOs support it. Site-specific conjugation (engineered cysteines like ThioMab, unnatural amino acids, glycan-based like GlyCLICK) is the emerging platform for cleaner drug-antibody ratio (DAR) control and homogeneity. CDMOs differ in which conjugation platforms they've validated at GMP scale. Sponsors should confirm not just the CDMO's conjugation menu but demonstrated DAR consistency at intended commercial scale and the CDMO's process for handling homogeneity outliers.
How CDMO Signal computes the ADC ranking
The ADC Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications, Warning Letter history, and EMA/MHRA GMP certificate density — this pillar carries particular weight for ADC because HPAPI containment is inspection-verified and regulatory posture on ADC is still evolving. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) draws on SEC filings and parent-company signals — ADC is capital-intensive with specialized facilities, so parent-company health matters for long-cycle commercial engagements. Capacity Intelligence (20%) tracks monitored trade press for facility expansions and ADC-specific capacity announcements. Full weightings at cdmosignal.com/methodology.
ADC (Antibody-Drug Conjugate) CDMOs — Frequently Asked Questions
Who are the top ADC (Antibody-Drug Conjugate) CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked ADC (Antibody-Drug Conjugate) CDMOs include AGC Biologics, Lonza, Charles River Laboratories. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?
CDMO Signal tracks 7 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 94 EMA/MHRA GMP certificates across the group.
What's the difference between an ADC CDMO and a biologics CDMO?
A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.
Which CDMOs have made commercially-approved ADCs?
Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.
What HPAPI containment level should an ADC CDMO have?
OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.
Related modalities